Education
About Us
Working with TipRanks
Follow Us
IRLAB Therapeutics AB Class A (SE:IRLAB.A)
:IRLAB.A
RESEARCH TOOLSreports
Total Valuation
IRLAB Therapeutics AB Class A has a market cap or net worth of kr208.77M. The enterprise value is kr1.74B.
Market Capkr208.77M
Enterprise Valuekr1.74B
Share Statistics
IRLAB Therapeutics AB Class A has 51,788,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,788,630
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
IRLAB Therapeutics AB Class A’s return on equity (ROE) is -2.55 and return on invested capital (ROIC) is -80.72%.
Return on Equity (ROE)-2.55
Return on Assets (ROA)-0.61
Return on Invested Capital (ROIC)-80.72%
Return on Capital Employed (ROCE)-2.08
Revenue Per Employee3.05M
Profits Per Employee-2.68M
Employee Count31
Asset Turnover0.69
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of IRLAB Therapeutics AB Class A is -6.71. IRLAB Therapeutics AB Class A’s PEG ratio is 0.05.
PE Ratio-6.71
PS Ratio0.00
PB Ratio6.83
Price to Fair Value17.09
Price to FCF-13.60
Price to Operating Cash Flow-13.92
PEG Ratio0.05
Income Statement
In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 94.63M and earned -83.13M in profits. Earnings per share was -1.60.
Revenue94.63M
Gross Profit-92.42M
Operating Income-75.11M
Pretax Income-83.13M
Net Income-83.13M
EBITDA-68.07M
Earnings Per Share (EPS)-1.60
Cash Flow
In the last 12 months, operating cash flow was -21.05M and capital expenditures -199.00K, giving a free cash flow of -21.25M billion.
Operating Cash Flow-21.05M
Free Cash Flow-21.25M
Free Cash Flow per Share-0.41
Dividends & Yields
IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change-69.04%
50-Day Moving Average6.84
200-Day Moving Average10.54
Relative Strength Index (RSI)18.91
Average Volume (3m)76.74K
Important Dates
IRLAB Therapeutics AB Class A upcoming earnings date is Aug 27, 2025, TBA (Confirmed).
Last Earnings DateMay 7, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of 1.37%
Current Ratio0.80
Quick Ratio0.80
Debt to Market Cap0.10
Net Debt to EBITDA0.10
Interest Coverage Ratio-7.17
Taxes
In the past 12 months, IRLAB Therapeutics AB Class A has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
IRLAB Therapeutics AB Class A EV to EBITDA ratio is -8.10, with an EV/FCF ratio of -8.38.
EV to Sales5.82
EV to EBITDA-8.10
EV to Free Cash Flow-8.38
EV to Operating Cash Flow-8.40
Balance Sheet
IRLAB Therapeutics AB Class A has kr88.61M in cash and marketable securities with kr66.46M in debt, giving a net cash position of -kr22.14M billion.
Cash & Marketable Securitieskr88.61M
Total Debtkr66.46M
Net Cash-kr22.14M
Net Cash Per Share-kr0.43
Tangible Book Value Per Share-kr0.27
Margins
Gross margin is -181.94%, with operating margin of -79.38%, and net profit margin of -87.85%.
Gross Margin-181.94%
Operating Margin-79.38%
Pretax Margin-87.85%
Net Profit Margin-87.85%
EBITDA Margin-71.93%
EBIT Margin-76.78%
Analyst Forecast
The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1643.36%
EPS Growth Forecast50.36%